RecruitingPhase 1NCT07525141

A Study of JNJ-1761981 in Participants With Solid Tumors

Phase 1 Study of Intratumoral Administration of JNJ-1761981 ER, an Extended Release Chemotherapy, in Participants With Solid Tumors

Sponsor

Johnson & Johnson Enterprise Innovation Inc.

Enrollment

66 participants

Start Date

May 18, 2026

Study Type

INTERVENTIONAL

Conditions

Neoplasms

Summary

The purpose of Part 1 of this study is to determine a safe, tolerable, and feasible recommended total dose of intratumorally administered JNJ-1761981. The purpose of Part 2 of this study is to identify the optimal volumetric dose of JNJ-1761981 for the treatment of tumor lesions.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Cetrelimab and a drug called JNJ-1761981 for people with neoplasms. The study is currently recruiting participants at 2 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.